The GSTZ1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line, designed for loss-of-function studies of glutathione S-transferase zeta 1 (GSTZ1). This gene-disrupted model enables investigation of GSTZ1-dependent metabolic and signaling pathways without reliance on pharmacological inhibitors, providing a clean genetic background for functional analyses.
HT29 is an established human colorectal adenocarcinoma epithelial cell line widely employed as an in vitro model for intestinal epithelial biology and colon cancer research. Its well-characterized phenotype, including intact epithelial polarity, moderate differentiation capacity, and robust growth in standard culture conditions, makes it suitable for studying tumor cell metabolism, drug response, and signaling perturbations introduced by genetic knockout.
GSTZ1 catalyzes the glutathione-dependent isomerization of maleylacetoacetate to fumarylacetoacetate in the tyrosine/phenylalanine degradation pathway, generating substrates for fumarylacetoacetate hydrolase to produce fumarate and acetoacetate. It also conjugates glutathione to dichloroacetate and other electrophiles. GSTZ1 expression is regulated by the NFE2L2 (Nrf2) transcription factor, which is suppressed by KEAP1 and activated by oxidative stress and xenobiotics such as sulforaphane and dichloroacetate. GSTZ1 functions as a homodimer with glutathione as a co-substrate, directly coupling its enzymatic activity to cellular redox balance and glutathione metabolism.
In HT29 colorectal cancer cells, GSTZ1 knockout is expected to impair tyrosine catabolism, leading to accumulation of upstream metabolites including maleylacetoacetate and potentially altering the cellular redox environment through glutathione depletion. Given the established role of glutathione in chemoresistance, this model provides a tool to dissect the contribution of GSTZ1 to glutathione-dependent drug detoxification pathways in colon cancer. Moreover, disruption of GSTZ1 may sensitize cells to dichloroacetate toxicity or oxidative stress, revealing metabolic vulnerabilities that could be exploited therapeutically.
Typical experimental applications include evaluating tyrosine metabolite profiles via LC-MS, assessing GSTZ1 protein and transcript levels by western blotting and RT-qPCR, performing cell viability assays under dichloroacetate or oxidative stress conditions, measuring reactive oxygen species (ROS) and glutathione depletion, and conducting drug sensitivity and migration/invasion screens. This polyclonal knockout population is particularly suited for studying how GSTZ1 loss modulates metabolic pathways in colon cancer, influences the NFE2L2/KEAP1 signaling axis, and alters cellular responses to chemotherapeutics. For further inquiries regarding product specifications, lot validation, or technical support, please contact Ascent Research.
